Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
We used mean changes from the time of drug discontinuation to the specified cutoff point of follow-up (week 4, week 8, week 12, week 20, week 26, and week 52) and standard deviations (SDs) extracted from published data when reported
Doses above 1500mg show no additional benefit in clinical trials and may cause mild gastrointestinal discomfort in some individuals
As new therapies emerge, clinicians face a critical question: which modern therapy offers the best outcomesGLP-1 agonists or SGLT2 inhibitors
fj201800346R
over whether they may increase the risk for CV problems," said Marc Pfeffer of Harvard Medical School and Brigham and Women's Hospital in the US, who presented the results of the ELIXA trial of Sanofi's glucagon-like peptide-1 (GLP-1) agonist Lyxumia (lixisenatide) at the ADA
Welcome to the Weekly Rundown where the DDN editors cover this weeks top biotech and pharma news
US$ 29.04
US$ 27.16
US$ 25.03
US$ 29.58
